Development of serum-free, chemically defined conditions for human embryonic stem cell-derived fibrochondrogenesis

Eugene J. Koay, Kyriacos A. Athanasiou

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This study established serum-free, chemically defined conditions to generate fibrocartilage with human embryonic stem cells (hESCs). Three sequential experimental phases were performed to eliminate serum because of its variability and antigenic potential and characterize the performance of hESCs in serum-free and serum-based conditions. Each phase used a two-stage modular experiment: chondrogenic differentiation followed by scaffold-less tissue engineering, called self-assembly. Phase I studied serum effects, and showed that a 1% serum chondrogenic medium (CM) during differentiation resulted in uniform constructs, whereas a 20% serum CM did not. Furthermore, a no-serum CM during self-assembly led to a collagen content 50% to 200% greater than a 1% serum CM. Thus, a "serum standard" of 1% serum during differentiation and no serum during self-assembly was carried forward. Phase II compared this with serum-free formulations, using 5% knock-out serum replacer or 1-ng/mL transforming growth factor beta 1 (TGF-β1). The TGF-β1 group was chosen as a "serum-free standard" because it performed similarly to the serum standard in terms of morphological, biochemical, and biomechanical properties. In Phase III, the serum-free standard had significantly more collagen (100%) and greater tensile (∼150%) and compressive properties (∼80%) than the serum standard with TGF-β1 treatment during self-assembly. These advances are important to the understanding of mechanisms of chondrogenesis and creating clinically relevant stem cell therapies.

Original languageEnglish (US)
Pages (from-to)2249-2257
Number of pages9
JournalTissue Engineering - Part A
Volume15
Issue number8
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Stem cells
Self assembly
Transforming Growth Factor beta
Serum
Collagen
Scaffolds (biology)
Tissue engineering
Fibrochondrogenesis
Human Embryonic Stem Cells
Intercellular Signaling Peptides and Proteins
Fibrocartilage
Experiments
Chondrogenesis
Antigenic Variation
Tissue Engineering
Cell- and Tissue-Based Therapy

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Biochemistry
  • Biomedical Engineering

Cite this

Development of serum-free, chemically defined conditions for human embryonic stem cell-derived fibrochondrogenesis. / Koay, Eugene J.; Athanasiou, Kyriacos A.

In: Tissue Engineering - Part A, Vol. 15, No. 8, 01.08.2009, p. 2249-2257.

Research output: Contribution to journalArticle

@article{7002fc4ce0f34094bf5b74b9e7eca15e,
title = "Development of serum-free, chemically defined conditions for human embryonic stem cell-derived fibrochondrogenesis",
abstract = "This study established serum-free, chemically defined conditions to generate fibrocartilage with human embryonic stem cells (hESCs). Three sequential experimental phases were performed to eliminate serum because of its variability and antigenic potential and characterize the performance of hESCs in serum-free and serum-based conditions. Each phase used a two-stage modular experiment: chondrogenic differentiation followed by scaffold-less tissue engineering, called self-assembly. Phase I studied serum effects, and showed that a 1{\%} serum chondrogenic medium (CM) during differentiation resulted in uniform constructs, whereas a 20{\%} serum CM did not. Furthermore, a no-serum CM during self-assembly led to a collagen content 50{\%} to 200{\%} greater than a 1{\%} serum CM. Thus, a {"}serum standard{"} of 1{\%} serum during differentiation and no serum during self-assembly was carried forward. Phase II compared this with serum-free formulations, using 5{\%} knock-out serum replacer or 1-ng/mL transforming growth factor beta 1 (TGF-β1). The TGF-β1 group was chosen as a {"}serum-free standard{"} because it performed similarly to the serum standard in terms of morphological, biochemical, and biomechanical properties. In Phase III, the serum-free standard had significantly more collagen (100{\%}) and greater tensile (∼150{\%}) and compressive properties (∼80{\%}) than the serum standard with TGF-β1 treatment during self-assembly. These advances are important to the understanding of mechanisms of chondrogenesis and creating clinically relevant stem cell therapies.",
author = "Koay, {Eugene J.} and Athanasiou, {Kyriacos A.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1089/ten.tea.2008.0320",
language = "English (US)",
volume = "15",
pages = "2249--2257",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Development of serum-free, chemically defined conditions for human embryonic stem cell-derived fibrochondrogenesis

AU - Koay, Eugene J.

AU - Athanasiou, Kyriacos A.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - This study established serum-free, chemically defined conditions to generate fibrocartilage with human embryonic stem cells (hESCs). Three sequential experimental phases were performed to eliminate serum because of its variability and antigenic potential and characterize the performance of hESCs in serum-free and serum-based conditions. Each phase used a two-stage modular experiment: chondrogenic differentiation followed by scaffold-less tissue engineering, called self-assembly. Phase I studied serum effects, and showed that a 1% serum chondrogenic medium (CM) during differentiation resulted in uniform constructs, whereas a 20% serum CM did not. Furthermore, a no-serum CM during self-assembly led to a collagen content 50% to 200% greater than a 1% serum CM. Thus, a "serum standard" of 1% serum during differentiation and no serum during self-assembly was carried forward. Phase II compared this with serum-free formulations, using 5% knock-out serum replacer or 1-ng/mL transforming growth factor beta 1 (TGF-β1). The TGF-β1 group was chosen as a "serum-free standard" because it performed similarly to the serum standard in terms of morphological, biochemical, and biomechanical properties. In Phase III, the serum-free standard had significantly more collagen (100%) and greater tensile (∼150%) and compressive properties (∼80%) than the serum standard with TGF-β1 treatment during self-assembly. These advances are important to the understanding of mechanisms of chondrogenesis and creating clinically relevant stem cell therapies.

AB - This study established serum-free, chemically defined conditions to generate fibrocartilage with human embryonic stem cells (hESCs). Three sequential experimental phases were performed to eliminate serum because of its variability and antigenic potential and characterize the performance of hESCs in serum-free and serum-based conditions. Each phase used a two-stage modular experiment: chondrogenic differentiation followed by scaffold-less tissue engineering, called self-assembly. Phase I studied serum effects, and showed that a 1% serum chondrogenic medium (CM) during differentiation resulted in uniform constructs, whereas a 20% serum CM did not. Furthermore, a no-serum CM during self-assembly led to a collagen content 50% to 200% greater than a 1% serum CM. Thus, a "serum standard" of 1% serum during differentiation and no serum during self-assembly was carried forward. Phase II compared this with serum-free formulations, using 5% knock-out serum replacer or 1-ng/mL transforming growth factor beta 1 (TGF-β1). The TGF-β1 group was chosen as a "serum-free standard" because it performed similarly to the serum standard in terms of morphological, biochemical, and biomechanical properties. In Phase III, the serum-free standard had significantly more collagen (100%) and greater tensile (∼150%) and compressive properties (∼80%) than the serum standard with TGF-β1 treatment during self-assembly. These advances are important to the understanding of mechanisms of chondrogenesis and creating clinically relevant stem cell therapies.

UR - http://www.scopus.com/inward/record.url?scp=68749104500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68749104500&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2008.0320

DO - 10.1089/ten.tea.2008.0320

M3 - Article

C2 - 19231974

AN - SCOPUS:68749104500

VL - 15

SP - 2249

EP - 2257

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 8

ER -